OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Entry into a Material Definitive Agreement

OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Entry into a Material Definitive Agreement
Item.0Entry into a Material Definitive Agreement.

Story continues below

On September 1, 2017, Oxford Immunotec Ltd. (“OI Ltd.”), a wholly owned subsidiary of Oxford Immunotec Global PLC (“OI Global”), entered into a Second Amendment to Supply Agreement (the “Second Amendment”) with StemCell Technologies Canada Inc. f/k/a StemCell Technologies Inc. (“StemCell”).

The Second Amendment amends the Supply Agreement between OI Ltd. and StemCell effective January 31, 2008 (the “Agreement”), as amended by an Amendment to Supply Agreement dated October 26, 2011 (the “First Amendment”), to which StemCell supplies OI Ltd. with a product that can be used in performing tests leveraging our T-SPOT® technology. The Second Amendment establishes pricing and extends the terms of the Agreement until December 31, 2023.

The Agreement and First Amendment were originally filed as Exhibits10.19 and 10.20, respectively,to OI Global’sRegistrationStatementonFormS-1(FileNo.333-191737)filed onOctober15,2013.

The foregoing descriptions of the Agreement and the First Amendment do not purport to be complete and are subject to, and are qualified in their entirety by reference to the full and complete terms of the Agreement and the First Amendment which are incorporated by reference herein. In addition, the foregoing description of the Second Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full and complete terms of the Second Amendment, which will be filed as an exhibit to OI Global’s next periodic report.


About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.

OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Recent Trading Information

OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) closed its last trading session down -0.33 at 15.38 with 110,932 shares trading hands.

An ad to help with our costs